Skip to main content
OpenTrials
Completed

NCT Number: NCT03442582

Afluria Pregnancy Registry

The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with Afluria during pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza, Human Birth Defect Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Infections Orthomyxoviridae Infections Pregnancy RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

Female

Study type

Observational

Primary location

Syneos Health

Wilmington, North Carolina, 28405, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Enrollment and data collection will be coordinated through a coordination center (CC). The minimum eligibility criteria required for enrollment are as follows:

  • Sufficient information to confirm that the exposure of interest occurred during pregnancy and at which date.
  • Sufficient information to determine whether it concerns a prospectively enrolled subject, since retrospective cases are ineligible for enrollment.
  • Reporter (e.g. HCP) contact information to allow for follow-up

Exclusion criteria

  • N/A

Treatment and study plan

Afluria Influenza Vaccine

Biological

Afluria is a seasonal influenza vaccine

Vaccine exposure in routine care (no vaccination per protocol)

Other names: Afluria

Primary outcomes

  1. Safety Objective: Number of cases for pregnancy outcomes among women immunized as part of routine care with Afluria, a seasonal influenza vaccine, during pregnancy.

    Time frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination; a follow-up period of up to 40 weeks

    Pregnancy outcomes will be reported as one of the following: live birth, stillbirth, spontaneous abortion and elective termination

  2. Safety Objective: Number of cases with events of major congenital malformations among women immunized as part of routine care with Afluria, a seasonal influenza vaccine, during pregnancy.

    Time frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination; a follow-up period of up to 40 weeks

  3. Safety Objective: Number of cases of events of preterm birth among women immunized as part of routine care with Afluria, a seasonal influenza vaccine, during pregnancy.

    Time frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination; a follow-up period of up to 40 weeks

  4. Safety Objective: Number of cases of events of low birth weight among women immunized as part of routine care with Afluria, a seasonal influenza vaccine, during pregnancy.

    Time frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination; a follow-up period of up to 40 weeks

Sponsors and collaborators

Lead sponsor

Seqirus

Industry

Registry information

Official study title

A Prospective Observational Safety Study on Pregnancy Outcomes in Women Immunized With Afluria, a Seasonal Influenza Vaccine, During Pregnancy

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Feb 22, 2018
Registry last updated
Feb 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.